{"success":true,"data":{"pressRelease":{"id":"17931","rtpr_id":"nBw3GR2t7a","ticker":"EW","exchange":"NYSE","all_tickers":["EW"],"title":"Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue","author":"Business Wire","published_at":"2026-05-02T15:50:00.103Z","article_body":"Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards\nLifesciences’ Resilia Tissue\n\nEdwards Lifesciences (NYSE: EW) today announced 10-year results from the\nCOMMENCE aortic trial, reinforcing the long-term durability and sustained\nperformance of its proprietary RESILIA tissue. The data were presented at the\n106th American Association for Thoracic Surgery Annual Meeting.\n\nAs evidence increasingly supports treating patients earlier in the valve\ndisease pathway, the need for durable valve solutions continues to grow. The\nCOMMENCE trial provides prospective, 10-year data demonstrating the durability\nof Edwards’ RESILIA tissue and its role in lifetime management for patients\nwith aortic stenosis. To date, more than 500,000 patients worldwide have been\ntreated with Edwards’ surgical and transcatheter innovations featuring\nRESILIA tissue.\n\nAt 10 years, COMMENCE trial data showed that patients treated with Edwards’\nsurgical valves featuring RESILIA tissue experienced:\n\n\n * 97.9% freedom from structural valve deterioration (SVD)\n\n * 97.8% freedom from reoperation due to SVD\n\n * 98.6% freedom from non-structural valve dysfunction (other than PVL)\n\n * Sustained hemodynamic performance, including stable gradients and effective\norifice area over time\n\nFor patients, long-term durability matters because it can reduce the\nlikelihood of repeat procedures over a lifetime, helping preserve quality of\nlife as life expectancy increases.\n\n“These 10-year data from the COMMENCE trial suggest this tissue technology\nhas the potential to change the way we think about durability in biological\nvalves, including in younger patients,” said Lars G. Svensson, MD, PhD,\nchief of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic\nInstitute and professor of surgery at Cleveland Clinic. “What is striking is\nthe low rate of structural valve deterioration and need for reoperation, even\nthough the trial enrolled younger patients who historically face higher risks\nof valve deterioration, underscoring the importance of long-term evidence when\nphysicians are making treatment decisions with their patients.”\n\nFor nearly 70 years, Edwards has led structural heart innovation, advancing\nevidence generation that has helped set the standard for evaluating valve\nperformance, durability and treatment options in severe aortic stenosis. The\nCOMMENCE trial builds on the totality of Edwards’ clinical evidence,\nreinforcing the durability of outcomes supporting its surgical and\ntranscatheter therapies, including large, randomized, FDA-approved studies\nsuch as the PARTNER series of trials.\n\nThe PARTNER trial series advanced the field with long-term patient outcomes on\ntreatment with SAPIEN TAVR and SAVR, with 10 years of follow-up data. The new\nCOMMENCE trial data build on that foundation with the latest evidence on the\nlong-term durability of RESILIA tissue.\n\nRESILIA tissue was designed to enhance the durability of tissue valves by\nhelping resist calcification, a leading cause of valve failure over time. The\ntechnology combines advanced calcium blocking processes with dry storage to\nsupport long-term valve performance.\n\n“As patients live longer and expect to remain active, structural heart\ntherapies must be designed with lifetime care in mind,” said Bernard\nZovighian, Edwards’ CEO. “The COMMENCE 10-year study is the latest\naddition to our breadth of long-term data reflecting our commitment to\nadvancing durable valve technologies through continuous evidence development,\nso Heart Teams and patients can make informed decisions over time.”\n\nThe COMMENCE aortic trial is an FDA-approved, pivotal, prospective,\nmulticenter clinical study designed to evaluate the safety and effectiveness\nof a bioprosthetic valve with RESILIA tissue used in SAVR, with follow-up\nthrough 10 years. Safety endpoints were defined according to established\nguidelines and independently adjudicated.\n\nAbout Edwards Lifesciences\n\nEdwards Lifesciences is the leading global structural heart innovation\ncompany, driven by a passion to improve patient lives. Through breakthrough\ntechnologies, world-class evidence and partnerships with clinicians and\nhealthcare stakeholders, our employees are inspired by our patient-focused\nculture to deliver life-changing innovations to those who need them most.\nDiscover more at www.edwards.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.edwards.com&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=www.edwards.com&index=1&md5=7c7b53d85fdb3e5d06a7196052e53b0f)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fedwards-lifesciences%2Fposts%2F%3FfeedView%3Dall&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=LinkedIn&index=2&md5=4a0e3a9c73d67e5a33eb6b7224df45f1)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FEdwardslifesciences%2F&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=Facebook&index=3&md5=6d578b208e4b7f93473bb44151fe429b)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fedwardslifesciences%2F&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=Instagram&index=4&md5=2535d37133091a7dc535e568468d39e0)\nand YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FEdwardsGlobal&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=YouTube&index=5&md5=6325a799f2e88e11d8567c44c75c1782)\n.\n\nThis news release includes forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, but are not limited to, statements made by Mr. Zovighian and\nstatements regarding expected long-term durability and sustained performance,\nreduction of the likelihood of repeat procedures, therapies helping to\npreserve quality of life, outcomes of the surgical and transcatheter\ntherapies, expectations for remaining active, and other statements that are\nnot historical facts. Forward-looking statements are based on estimates and\nassumptions made by management of the company and are believed to be\nreasonable, though they are inherently uncertain and difficult to predict. Our\nforward-looking statements speak only as of the date on which they are made,\nand we do not undertake any obligation to update any forward-looking statement\nto reflect events or circumstances after the date of the statement. Investors\nare cautioned not to unduly rely on such forward-looking statements.\n\nForward-looking statements involve risks and uncertainties that could cause\nresults to differ materially from those expressed or implied by the\nforward-looking statements based on a number of factors as detailed in the\ncompany's filings with the Securities and Exchange Commission. These filings,\nalong with important safety information about our products, may be found at\nEdwards.com.\n\nEdwards, Edwards Lifesciences, the stylized E logo, COMMENCE, PARTNER,\nRESILIA, and SAPIEN are trademarks of Edwards Lifesciences Corporation or its\naffiliates. All other trademarks are the property of their respective owners.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260502326120/en/\n(https://www.businesswire.com/news/home/20260502326120/en/)\n\nMedia: Maureen Ranney, media@edwards.com \n(mailto:media@edwards.com) \nInvestors: Gerianne Sarte, investor_relations@edwards.com\n(mailto:investor_relations@edwards.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3GR2t7a","title":"Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue","author":"Business Wire","ticker":"EW","created":"2026-05-02T15:50:00.103Z","tickers":["EW"],"exchange":"NYSE","article_body":"Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards\nLifesciences’ Resilia Tissue\n\nEdwards Lifesciences (NYSE: EW) today announced 10-year results from the\nCOMMENCE aortic trial, reinforcing the long-term durability and sustained\nperformance of its proprietary RESILIA tissue. The data were presented at the\n106th American Association for Thoracic Surgery Annual Meeting.\n\nAs evidence increasingly supports treating patients earlier in the valve\ndisease pathway, the need for durable valve solutions continues to grow. The\nCOMMENCE trial provides prospective, 10-year data demonstrating the durability\nof Edwards’ RESILIA tissue and its role in lifetime management for patients\nwith aortic stenosis. To date, more than 500,000 patients worldwide have been\ntreated with Edwards’ surgical and transcatheter innovations featuring\nRESILIA tissue.\n\nAt 10 years, COMMENCE trial data showed that patients treated with Edwards’\nsurgical valves featuring RESILIA tissue experienced:\n\n\n * 97.9% freedom from structural valve deterioration (SVD)\n\n * 97.8% freedom from reoperation due to SVD\n\n * 98.6% freedom from non-structural valve dysfunction (other than PVL)\n\n * Sustained hemodynamic performance, including stable gradients and effective\norifice area over time\n\nFor patients, long-term durability matters because it can reduce the\nlikelihood of repeat procedures over a lifetime, helping preserve quality of\nlife as life expectancy increases.\n\n“These 10-year data from the COMMENCE trial suggest this tissue technology\nhas the potential to change the way we think about durability in biological\nvalves, including in younger patients,” said Lars G. Svensson, MD, PhD,\nchief of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic\nInstitute and professor of surgery at Cleveland Clinic. “What is striking is\nthe low rate of structural valve deterioration and need for reoperation, even\nthough the trial enrolled younger patients who historically face higher risks\nof valve deterioration, underscoring the importance of long-term evidence when\nphysicians are making treatment decisions with their patients.”\n\nFor nearly 70 years, Edwards has led structural heart innovation, advancing\nevidence generation that has helped set the standard for evaluating valve\nperformance, durability and treatment options in severe aortic stenosis. The\nCOMMENCE trial builds on the totality of Edwards’ clinical evidence,\nreinforcing the durability of outcomes supporting its surgical and\ntranscatheter therapies, including large, randomized, FDA-approved studies\nsuch as the PARTNER series of trials.\n\nThe PARTNER trial series advanced the field with long-term patient outcomes on\ntreatment with SAPIEN TAVR and SAVR, with 10 years of follow-up data. The new\nCOMMENCE trial data build on that foundation with the latest evidence on the\nlong-term durability of RESILIA tissue.\n\nRESILIA tissue was designed to enhance the durability of tissue valves by\nhelping resist calcification, a leading cause of valve failure over time. The\ntechnology combines advanced calcium blocking processes with dry storage to\nsupport long-term valve performance.\n\n“As patients live longer and expect to remain active, structural heart\ntherapies must be designed with lifetime care in mind,” said Bernard\nZovighian, Edwards’ CEO. “The COMMENCE 10-year study is the latest\naddition to our breadth of long-term data reflecting our commitment to\nadvancing durable valve technologies through continuous evidence development,\nso Heart Teams and patients can make informed decisions over time.”\n\nThe COMMENCE aortic trial is an FDA-approved, pivotal, prospective,\nmulticenter clinical study designed to evaluate the safety and effectiveness\nof a bioprosthetic valve with RESILIA tissue used in SAVR, with follow-up\nthrough 10 years. Safety endpoints were defined according to established\nguidelines and independently adjudicated.\n\nAbout Edwards Lifesciences\n\nEdwards Lifesciences is the leading global structural heart innovation\ncompany, driven by a passion to improve patient lives. Through breakthrough\ntechnologies, world-class evidence and partnerships with clinicians and\nhealthcare stakeholders, our employees are inspired by our patient-focused\nculture to deliver life-changing innovations to those who need them most.\nDiscover more at www.edwards.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.edwards.com&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=www.edwards.com&index=1&md5=7c7b53d85fdb3e5d06a7196052e53b0f)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fedwards-lifesciences%2Fposts%2F%3FfeedView%3Dall&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=LinkedIn&index=2&md5=4a0e3a9c73d67e5a33eb6b7224df45f1)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FEdwardslifesciences%2F&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=Facebook&index=3&md5=6d578b208e4b7f93473bb44151fe429b)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fedwardslifesciences%2F&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=Instagram&index=4&md5=2535d37133091a7dc535e568468d39e0)\nand YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FEdwardsGlobal&esheet=54527555&newsitemid=20260502326120&lan=en-US&anchor=YouTube&index=5&md5=6325a799f2e88e11d8567c44c75c1782)\n.\n\nThis news release includes forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\ninclude, but are not limited to, statements made by Mr. Zovighian and\nstatements regarding expected long-term durability and sustained performance,\nreduction of the likelihood of repeat procedures, therapies helping to\npreserve quality of life, outcomes of the surgical and transcatheter\ntherapies, expectations for remaining active, and other statements that are\nnot historical facts. Forward-looking statements are based on estimates and\nassumptions made by management of the company and are believed to be\nreasonable, though they are inherently uncertain and difficult to predict. Our\nforward-looking statements speak only as of the date on which they are made,\nand we do not undertake any obligation to update any forward-looking statement\nto reflect events or circumstances after the date of the statement. Investors\nare cautioned not to unduly rely on such forward-looking statements.\n\nForward-looking statements involve risks and uncertainties that could cause\nresults to differ materially from those expressed or implied by the\nforward-looking statements based on a number of factors as detailed in the\ncompany's filings with the Securities and Exchange Commission. These filings,\nalong with important safety information about our products, may be found at\nEdwards.com.\n\nEdwards, Edwards Lifesciences, the stylized E logo, COMMENCE, PARTNER,\nRESILIA, and SAPIEN are trademarks of Edwards Lifesciences Corporation or its\naffiliates. All other trademarks are the property of their respective owners.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260502326120/en/\n(https://www.businesswire.com/news/home/20260502326120/en/)\n\nMedia: Maureen Ranney, media@edwards.com \n(mailto:media@edwards.com) \nInvestors: Gerianne Sarte, investor_relations@edwards.com\n(mailto:investor_relations@edwards.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-02T15:50:00.14807749Z","server_sent_at_ms":1777737000148},"received_at":"2026-05-02T15:50:00.207Z","source_url":"https://www.businesswire.com/news/home/20260502326120/en/"},"analysis":null,"durationMs":null,"modelName":null}}